Jazz Pharmaceuticals plc · JAZZ · FY2025 Q4 · Calendar Q1 2026
Jazz delivered record 2025 revenue; 2026 growth hinges on launches and pipeline
Jazz’s record 2025 revenue and expected 2026 growth reflect contributions from its CNS and oncology products, while new launches and pipeline milestones create further opportunities. Generic competition for oxybate products and the clinical and regulatory execution required for pipeline plans remain material counterweights.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about JAZZ FY2025 Q4
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management reported record 2025 revenue of $4.3 billion and 10% year-over-year fourth-quarter growth, and described a successful Modeyso launch. The call also outlined 2026 priorities for zanidatamab, Modeyso, Epidiolex and Zepzelca, while acknowledging generic pressure on Xywav.
Guidance delta
Management maintained its 2026 outlook. The supplied analysis characterizes expected top-line growth as modest, approximately 2.5% at the midpoint, with double-digit growth expected in rare oncology and epilepsy segments.
Key takeaways
- 2025 revenue reached a record $4.3 billion, supported by Xywav, Epidiolex, Modeyso and Zepzelca.
- Modeyso generated $48 million in sales within four months, according to the supplied call analysis.
- Management cited zanidatamab’s planned gastric-cancer launch in the second half of 2026 and further clinical development in breast cancer.
- Generic competition and payer actions remain potential pressure points for Xywav and Xyrem.
Management priorities
- Expand zanidatamab in gastric cancer and advance its breast-cancer program.
- Build Modeyso adoption and pursue a potential first-line indication subject to ACTION trial results.
- Develop Epidiolex through adult-patient expansion, new formulations and a Phase Ib focal-onset-seizure study.
- Continue rare-disease portfolio development and consider additional M&A and licensing.
Follow JAZZ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationJazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.…
Historical context
All JAZZ earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | FY2026 Q3 · Calendar Q4 2026 | -1.2% | -1.0% | Vertex lifts 2026 outlook as CF franchise and newer products support growth |
| BMRN BioMarin Pharmaceutical Inc. | FY2026 Q3 · Calendar Q4 2026 | +376.0% | -1.8% | BioMarin’s Q3 growth meets a lower full-year outlook |
| IDXX IDEXX Laboratories, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.2% | +21.8% | IDEXX Raises FY2026 Outlook on Diagnostics and Software Growth |
| NBIX Neurocrine Biosciences, Inc. | FY2026 Q3 · Calendar Q4 2026 | +72.3% | -0.5% | Neurocrine Raises INGREZZA Outlook as Core Products Grow |
| AXSM Axsome Therapeutics, Inc. | FY2026 Q3 · Calendar Q4 2026 | +60.6% | -5.8% | Axsome’s Q3 growth broadens, while reimbursement and trial execution remain key tests |
| TEM Tempus AI, Inc. | FY2026 Q3 · Calendar Q4 2026 | +174.7% | +8.7% | Tempus Q3 growth broadens across diagnostics and data |
Latest beats and misses
Who reports nextBeat on EPS
- TSEMFY2026 Q3 · November 2, 2026+7.5% EPS-6.7% move
- CLXFY2027 Q1 · November 2, 2026+44.9% EPS+2.2% move
- AAPLFY2026 Q4 · November 2, 2026+3.0% EPS-1.8% move
- PLTRFY2026 Q3 · November 2, 2026+8.3% EPS-3.1% move
- ETRFY2026 Q3 · November 2, 2026+14.5% EPS-0.2% move
- OFY2026 Q3 · November 2, 2026+5.7% EPS+1.1% move
Missed on EPS
- VRTXFY2026 Q3 · November 2, 2026-1.2% EPS-1.0% move
- PEGFY2026 Q3 · November 2, 2026-3.4% EPS+0.1% move
- RYAAYFY2027 Q2 · November 2, 2026-0.3% EPS+2.9% move
- GLPIFY2026 Q3 · October 29, 2026-11.5% EPS-1.3% move
- LYBFY2026 Q3 · October 30, 2026-1.2% EPS+5.0% move
- CCJFY2026 Q3 · October 30, 2026-101.4% EPS-7.9% move
Get the JAZZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-11-03T10:50:50.048748+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-03T10:50:50.045901+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-03. For educational purposes only; not investment advice.